Roche's BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis trialsPhase... | May 17, 2023